Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung Cancer | NEJM
Progression-free survival by IRC Shown is the Kaplan-Meier curve for... | Download Scientific Diagram
Cancers | Free Full-Text | Brigatinib and Alectinib for ALK Rearrangement-Positive Advanced Non-Small Cell Lung Cancer with or without Central Nervous System Metastasis: A Systematic Review and Network Meta-Analysis | HTML
A) Kaplan-Meier curve of progression-free survival (PFS) in the... | Download Scientific Diagram
First-Line PFS - ALECENSA® (alectinib)
First-Line PFS - ALECENSA® (alectinib)
Supplemental Materials for Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial - The Lancet
Comparative effectiveness from a single-arm trial and real-world data: alectinib versus ceritinib | Journal of Comparative Effectiveness Research
ALK Mutation Status Before and After Alectinib Treatment in Locally Advanced or Metastatic ALK-Positive NSCLC: Pooled Analysis of Two Prospective Trials - Journal of Thoracic Oncology
Progression-free survival of patients with ALK-positive NSCLC | Download Scientific Diagram
Expanding treatment options in NSCLC patients with rare mutations: ALK, ROS1, MET, BRAF - memoinOncology
ALK-positive NSCLC: updates on crizotinib and alectinib - memoinOncology
Roche - European Commission approves Roche's Alecensa (alectinib) as first-line treatment in ALK-positive lung cancer
Frontiers | Brain Metastases in Oncogene-Addicted Non-Small Cell Lung Cancer Patients: Incidence and Treatment | Oncology
Supplemental Materials for Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial - The Lancet Oncology
Alectinib & crizotinib improved survival outcomes of NSCLC | OTT
How the CROWN Study Affects Treatment of Patients With ALK-Positive Metastatic Non–Small Cell Lung Cancer
Pooled overall survival and safety data from the pivotal phase II studies (NP28673 and NP28761) of alectinib in ALK-positive non-small-cell lung cancer - Lung Cancer
JALEX Phase III Trial of Alectinib versus Crizotinib
Potent treatment options in ALK– and MET-positive disease - memoinOncology
Natural History and Factors Associated with Overall Survival in Stage IV ALK-Rearranged Non–Small Cell Lung Cancer - Journal of Thoracic Oncology
Alectinib versus chemotherapy in crizotinib-pretreated anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer: results from the phase III ALUR study - Annals of Oncology
Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-Positive Advanced Non–Small Cell Lung Cancer in the Global Phase III ALEX Study -
Alectinib Yields Better Overall Survival Than Ceritinib in ALK-Positive Non–Small Cell Lung Cancer
YIR On Demand Lung Benjamin Levy, MD Assistant Professor - ppt download
